158 related articles for article (PubMed ID: 27203389)
21. [Clinical and laboratory prognostic parameters for leukemic types of chronic lymphoproliferative diseases].
Kardum-Skelin I; Planinc-Peraica A; Ostojić Kolonić S; Radić-Kristo D; Milas M; Vrhovac R; Sustercić D; Minigo H; Jaksić B
Acta Med Croatica; 2008 Oct; 62(4):351-64. PubMed ID: 19205412
[TBL] [Abstract][Full Text] [Related]
22. Effect of rapamycin on mouse chronic lymphocytic leukemia and the development of nonhematopoietic malignancies in Emu-TCL1 transgenic mice.
Zanesi N; Aqeilan R; Drusco A; Kaou M; Sevignani C; Costinean S; Bortesi L; La Rocca G; Koldovsky P; Volinia S; Mancini R; Calin G; Scott CP; Pekarsky Y; Croce CM
Cancer Res; 2006 Jan; 66(2):915-20. PubMed ID: 16424025
[TBL] [Abstract][Full Text] [Related]
23. Chromogranin A protects vessels against tumor necrosis factor alpha-induced vascular leakage.
Ferrero E; Scabini S; Magni E; Foglieni C; Belloni D; Colombo B; Curnis F; Villa A; Ferrero ME; Corti A
FASEB J; 2004 Mar; 18(3):554-6. PubMed ID: 14734634
[TBL] [Abstract][Full Text] [Related]
24. A new chromogranin A-dependent angiogenic switch activated by thrombin.
Crippa L; Bianco M; Colombo B; Gasparri AM; Ferrero E; Loh YP; Curnis F; Corti A
Blood; 2013 Jan; 121(2):392-402. PubMed ID: 23190532
[TBL] [Abstract][Full Text] [Related]
25. Chromogranin A regulates tumor self-seeding and dissemination.
Dondossola E; Crippa L; Colombo B; Ferrero E; Corti A
Cancer Res; 2012 Jan; 72(2):449-59. PubMed ID: 22139379
[TBL] [Abstract][Full Text] [Related]
26. Vasostatin I (CgA17-76) vasoconstricts rat splanchnic vascular bed but does not affect central cardiovascular function.
Rahman AA; Shahid IZ; Fong AY; Hammond AM; Pilowsky PM
Auton Neurosci; 2012 Jan; 166(1-2):22-8. PubMed ID: 21937287
[TBL] [Abstract][Full Text] [Related]
27. Circulating chromogranin A and its fragments as diagnostic and prognostic disease markers.
Corti A; Marcucci F; Bachetti T
Pflugers Arch; 2018 Jan; 470(1):199-210. PubMed ID: 29018988
[TBL] [Abstract][Full Text] [Related]
28. Spatiotemporal Regulation of Tumor Angiogenesis by Circulating Chromogranin A Cleavage and Neuropilin-1 Engagement.
Dallatomasina A; Gasparri AM; Colombo B; Sacchi A; Bianco M; Daniele T; Esposito A; Pastorino F; Ponzoni M; Marcucci F; Curnis F; Corti A
Cancer Res; 2019 Apr; 79(8):1925-1937. PubMed ID: 30796053
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of trisomy 12 by fluorescence in situ hybridization in peripheral blood, bone marrow and lymph nodes of patients with B-cell chronic lymphocytic leukemia.
Liso V; Capalbo S; Lapietra A; Pavone V; Guarini A; Specchia G
Haematologica; 1999 Mar; 84(3):212-7. PubMed ID: 10189384
[TBL] [Abstract][Full Text] [Related]
30. Recombinant N-terminal fragments of chromogranin-A modulate cardiac function of the Langendorff-perfused rat heart.
Cerra MC; De Iuri L; Angelone T; Corti A; Tota B
Basic Res Cardiol; 2006 Jan; 101(1):43-52. PubMed ID: 16151967
[TBL] [Abstract][Full Text] [Related]
31. EphrinA4 plays a critical role in α4 and αL mediated survival of human CLL cells during extravasation.
Flores MA; Fortea P; Trinidad EM; García D; Soler G; Ortuño FJ; Zapata AG; Alonso-Colmenar LM
Oncotarget; 2016 Jul; 7(30):48481-48500. PubMed ID: 27374180
[TBL] [Abstract][Full Text] [Related]
32. The vascular endothelial growth factor receptor tyrosine kinase inhibitors vatalanib and pazopanib potently induce apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo.
Paesler J; Gehrke I; Gandhirajan RK; Filipovich A; Hertweck M; Erdfelder F; Uhrmacher S; Poll-Wolbeck SJ; Hallek M; Kreuzer KA
Clin Cancer Res; 2010 Jul; 16(13):3390-8. PubMed ID: 20570929
[TBL] [Abstract][Full Text] [Related]
33. The chromogranin A-derived peptides vasostatin-I and catestatin as regulatory peptides for cardiovascular functions.
Helle KB
Cardiovasc Res; 2010 Jan; 85(1):9-16. PubMed ID: 19640932
[TBL] [Abstract][Full Text] [Related]
34. Chromogranin A restricts drug penetration and limits the ability of NGR-TNF to enhance chemotherapeutic efficacy.
Dondossola E; Gasparri AM; Colombo B; Sacchi A; Curnis F; Corti A
Cancer Res; 2011 Sep; 71(17):5881-90. PubMed ID: 21799030
[TBL] [Abstract][Full Text] [Related]
35. Nutlin-3 downregulates the expression of the oncogene TCL1 in primary B chronic lymphocytic leukemic cells.
Voltan R; di Iasio MG; Bosco R; Valeri N; Pekarski Y; Tiribelli M; Secchiero P; Zauli G
Clin Cancer Res; 2011 Sep; 17(17):5649-55. PubMed ID: 21753157
[TBL] [Abstract][Full Text] [Related]
36. Parastatin (porcine chromogranin A347-419), a novel chromogranin A-derived peptide, inhibits parathyroid cell secretion.
Fasciotto BH; Trauss CA; Greeley GH; Cohn DV
Endocrinology; 1993 Aug; 133(2):461-6. PubMed ID: 8344192
[TBL] [Abstract][Full Text] [Related]
37. In vitro and In vivo selective antitumor activity of Edelfosine against mantle cell lymphoma and chronic lymphocytic leukemia involving lipid rafts.
Mollinedo F; de la Iglesia-Vicente J; Gajate C; Estella-Hermoso de Mendoza A; Villa-Pulgarin JA; de Frias M; Roué G; Gil J; Colomer D; Campanero MA; Blanco-Prieto MJ
Clin Cancer Res; 2010 Apr; 16(7):2046-54. PubMed ID: 20233887
[TBL] [Abstract][Full Text] [Related]
38. Chronic lymphocytic leukemia with prostate infiltration mediated by specific clonal membrane-bound IgM.
Bogdan CA; Alexander AA; Gorny MK; Matute R; Marjanovic N; Zolla-Pazner S; Walden PD; Furneaux HM; Sidhu GS; Jacobson DR
Cancer Res; 2003 May; 63(9):2067-71. PubMed ID: 12727821
[TBL] [Abstract][Full Text] [Related]
39. Expression and regulation of COP1 in chronic lymphocytic leukemia cells for promotion of cell proliferation and tumorigenicity.
Fu C; Gong Y; Shi X; Shi H; Wan Y; Wu Q; Xu K
Oncol Rep; 2016 Mar; 35(3):1493-500. PubMed ID: 26717976
[TBL] [Abstract][Full Text] [Related]
40. Xenograft models of chronic lymphocytic leukemia: problems, pitfalls and future directions.
Bertilaccio MT; Scielzo C; Simonetti G; Ten Hacken E; Apollonio B; Ghia P; Caligaris-Cappio F
Leukemia; 2013 Mar; 27(3):534-40. PubMed ID: 23041721
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
